Author’s response to reviews

Title: The Effects Of Desflurane And Sevoflurane On Nesfatin1 Levels In Laparoscopic Cholecystectomy

Authors:
Ayça Tuba Dumanlı Özcan (draycaozcan@gmail.com)
Cemile Altın Balcı (drcemilebalci@gmail.com)
Serpil Erdoğan (drserpilerdogan@gmail.com)
Merve Ergin (drmerveergin@gmail.com)
Ali Çiftçi (draliciftci@gmail.com)
Halil Kara (drhalilikara@gmail.com)
Şemsi Aksoy (drmaksoy@gmail.com)
Abdulkadir But (akadirbut@gmail.com)

Version: 3 Date: 03 Dec 2017

Author’s response to reviews:

PBANE-D-17-00242_R2 Martin Schlaepfer (Reviewer 1)

Keywords: p2l15: inhaler Anesthetic Agents -> please change to volatile anesthetics
It is corrected

Abstract: p2l25: inhaled agents -> volatile anesthetics
It is corrected.

p2l25: In the introduction there is now an explanation why nesfatin-1 was measured (stress level associated protein), this information is still missing in the abstract section. It was explained in abstract.

p2l47: entubation -> intubation It is corrected
p2l49: aldrate score -> aldrete score It is corrected
p3l8: inhaler Anesthetic Agents -> please change to volatile anesthetics It is corrected
Background

p3l22: …concentration of 30 pmol/L it is corrected

p4l12: the subtitle "conclusion" is misleading in the background section. Please remove it is removed.

p3l45: change to: The patient's heart rate (HR), mean, systolic and diastolic arterial pressures (MAP, SAP, DAP), peripheral O2 saturation (SpO2) were monitored. It is corrected

p4l37: aldrate -> aldrete It is corrected

p5l22: why does the sample size calculation say, there are 42 patients needed in the study, but the authors have included only 40 patients? Also in table 1 there are still 40 patients… it is corrected.

Table 1. Demographic and clinical features of groups

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Desflurane (n=21)</th>
<th>Sevoflurane (n=21)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>49.6±9.3</td>
<td>49.8±10.9</td>
<td>0.943†</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td>0.306‡</td>
</tr>
<tr>
<td>Male</td>
<td>4 (19.0%)</td>
<td>8 (38.1%)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>17 (81.0%)</td>
<td>13 (61.9%)</td>
<td></td>
</tr>
<tr>
<td>ASA</td>
<td></td>
<td></td>
<td>1.000‡</td>
</tr>
<tr>
<td>I</td>
<td>11 (52.4%)</td>
<td>10 (47.6%)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>10 (47.6%)</td>
<td>11 (52.4%)</td>
<td></td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.64±0.10</td>
<td>1.66±0.10</td>
<td>0.566†</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>84.0±17.9</td>
<td>79.3±13.2</td>
<td>0.366†</td>
</tr>
<tr>
<td>Body-mass index (kg/m2)</td>
<td>31.2±5.9</td>
<td>28.9±5.2</td>
<td>0.210†</td>
</tr>
<tr>
<td>Comorbid diseases</td>
<td>10 (47.6%)</td>
<td>11 (52.4%)</td>
<td>1.000‡</td>
</tr>
<tr>
<td>DM</td>
<td>1 (4.8%)</td>
<td>6 (28.6%)</td>
<td>0.093</td>
</tr>
<tr>
<td>HT</td>
<td>7 (33.3%)</td>
<td>6 (28.6%)</td>
<td>1.000‡</td>
</tr>
<tr>
<td>Asthma</td>
<td>2 (9.5%)</td>
<td>4 (19.0%)</td>
<td>0.663</td>
</tr>
<tr>
<td>Others</td>
<td>4 (19.0%)</td>
<td>3 (14.3%)</td>
<td>1.000</td>
</tr>
</tbody>
</table>

† Student's t test, ‡ Continuity corrected chi-square test, ¶ Fisher's exact test. Others: thyroid, hematological, neurological and rheumatological diseases.

Figure 1: the unit for nesfatin levels (pg) is missing on the y-axis

Discussion: p9l58: you still talk about an increase in nesfatin-1 but your statistic proves otherwise: You did not have a change in nesfatin-levels neither pre- vs. postoperatively, nor depending on the treatment (sevoflurane vs. desflurane). Please revise. It is corrected.

Gaetano Scaramuzzo (Reviewer 2)
The abstract conclusions should be reviewed in accordance to the conclusions of the study. It is revised as you mentioned.

The discussion should focus less on the biological effects of the nesfatin-1 and more on the results of the work. Please verify the number of patients (there are different data through the manuscript). It is revised as you mentioned.

Specific comments:

Abstract: please revise the abstract's conclusion in accordance to the aim of the study and to the title of the study. Explain what is the final effect of the two different anaesthetic gases of postoperative nesfatin (no increase in both groups after surgery; no difference between nesfatin-1 levels between groups after surgery)

It is corrected;

‘In conclusion, this study results suggest that nesfatin-1 levels is not affected by different volatile anesthetics related to surgical stress response in patients undergoing laparoscopic cholecystectomy.’

Page 6, line 49. Aldrete score not aldrate score – it is corrected.

Page 8: "Forty patients with American Society Anesthesiology (ASA) Class I-II". I already suggested in the first revision to verify this data according to what is written in the tables and in the result section (42 patients or 40? Please revise). Revise also the abstract (40 patients? 42? Not clear!)

It is corrected.

Page 9, line 25: "But sevoflurane and desflurane concentration weren't changed during the anesthesia maintenance". Please consider eliminating "But" at the beginning of the sentence. – It is corrected.

Page 9 line 37: Aldrete not aldrate It is corrected

- Page 14, line 58: "While there is an elevation in nesfatin-1 levels" consider revising this sentence, since there was no statistically significant difference in both groups before and after surgery (so there was no statistically significant increase in the nesfatin-1 level). It is corrected.

- Page 18: there are no conclusion regarding the postoperative levels of nesfatin-1. Consider reviewing with this information since was one of the aim of the study. ). It is corrected.